OnKure Therapeutics (NASDAQ:OKUR) Trading 4% Higher – Still a Buy?

OnKure Therapeutics (NASDAQ:OKUR)’s share price traded up 4% during mid-day trading on Tuesday . The company traded as high as $9.38 and last traded at $8.60. 87,917 shares changed hands during trading, an increase of 110% from the average session volume of 41,913 shares. The stock had previously closed at $8.27.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on OKUR. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of OnKure Therapeutics in a report on Friday, November 8th. Lifesci Capital raised shares of OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, October 10th. Oppenheimer started coverage on shares of OnKure Therapeutics in a research report on Thursday, October 10th. They issued an “outperform” rating and a $35.00 target price on the stock. Leerink Partners started coverage on shares of OnKure Therapeutics in a research report on Thursday, December 5th. They issued an “outperform” rating and a $33.00 price target for the company. Finally, Leerink Partnrs upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, OnKure Therapeutics has an average rating of “Buy” and an average target price of $36.00.

OnKure Therapeutics Stock Performance

The firm has a market capitalization of $28.48 million, a P/E ratio of -0.70 and a beta of 0.14. The stock’s 50 day moving average price is $13.78.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.13). Sell-side analysts anticipate that OnKure Therapeutics will post -4.05 earnings per share for the current year.

About OnKure Therapeutics

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.